Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal-cancer - first results of a randomized multicenter study by the association-of-medical-oncology-of-the-german-cancer-society (aio)
Kohne, Ch × Wilke, H Hecker, H Schöffski, Patrick Kaufer, C Rauschecker, H Andreesen, R Ohl, U Lange, Hj Klaassen, U Westerhausen, M Hiddemann, W Hennemann, B Schott, G Bade, J Strohmeyer, G Harstrick, A Schubert, U Bokemeyer, C Schmoll, Hj #
Kluwer academic publ
Annals of oncology vol:6 issue:5 pages:461-466
Background: High-dose 5-FU given weekly as a 24-h infusion in combination with folinic acid (FA) has been associated with low toxicity and a high response rate. Interferon-alpha (IFN) either alone or in combination with FA has also improved treatment results by modulating 5-FU activity. We therefore initiated a randomized multicenter trial comparing the ability of FA or IFN to modulate infusional 5-FU. The statistical design using a sequential analysis allows us to report on the comparison of 5-FU/FA vs. 5-FU/FA/IFN while randomization of patients into 5-FU/FA vs. 5 FU/IFN continues.